Another positive story for GLP-1 weight loss drugs has been announced, suggesting medications like Wegovy may have potential benefits in treating heart failure among patients with obesity and diabetes. Typically prescribed for weight management in high-risk populations, this positive news is likely to continue the high demand for these drug substances.

Madrigal Pharmaceuticals' new drug, Rezdiffra, has recently been approved as the first treatment for metabolic dysfunction-associated steatohepatitis (MASH). Gastroenterologists, are highly optimistic about its potential in managing patients with moderate to advanced fibrosis and suffering from severe liver conditions such as cirrhosis.

Expanding beyond its COVID-19 vaccines, Moderna reported positive trial results for vaccines against norovirus, Epstein-Barr virus, and Varicella-Zoster virus, aiming for final-stage studies and marketing a positive move towards diversifying its product.

Amgen's MariTide shows promising results in early-stage trials, offering a novel approach to weight loss by both activating and blocking gastric inhibitory polypeptide (GIP) receptors, potentially mimicking the body's natural regulation process.

Redx Pharma has initiated a Phase I clinical trial for RXC008, a new class of ROCK inhibitor aimed at treating fibrostenotic Crohn's disease. This study, focusing on safety and pharmacokinetics, marks a significant step in addressing a condition currently limited to surgical interventions. Results are anticipated by year's end.

Janux Therapeutics' stock value soared after early trial results suggested its immunotherapy technology could offer potent, safer treatments for solid tumors.

Viking Therapeutics' weight loss drug showed up to 15% body weight reduction in a 13-week mid-stage trial, surpassing similar drugs from Eli Lilly and Novo Nordisk. However, further validation is needed in Phase 3 trials.

GSK's oral antibiotic, gepotidacin, has shown effectiveness in a late-stage gonorrhea trial, matching the current treatment regimen's success. It's also under consideration for urinary tract infections, with approvals sought later this year.

Zealand Pharma's stock soared after announcing positive Phase 2 trial results for survodutide, a liver disease treatment with potential in the obesity market.

IQVIA has published a report "Global Trends in R&D 2024" exploring current developments and prospects in pharmaceutical research and development.

Nanoform, the medicine performance-enhancing company, announced that it has won a grant of up to 4.3 million euros from Business Finland, the Finnish government organization for innovation funding and trade.

Lantern Pharma is advancing a new ADC program aimed at various solid tumor cancers. The program which uses a cryptophycin-based ADC has already shown very high potency in preclinical tests. 

Bristol Myers Squibb (BMS) has partnered with deep tech company VantAI in a $674 million deal for its Generative AI-driven drug discovery platform.

The European Commission has approved CASGEVY™ (exagamglogene autotemcel) - the first CRISPR/Cas9 gene-edited therapy, for treating severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in patients aged 12 and older.

Latigo Biotherapeutics have just announced $135 million in Series A financing to develop non-opioid medicines for patients suffering from acute and chronic pain​​.

Tirzepatide, Eli Lilly’s weight-loss drug most referred to by its brand names Mounjaro and Zepbound, has shown beneficial effects in relation to weight loss and glucose control. A

Further demonstrating the demand for weight loss drugs, recently published data for Amgen’s experimental obesity drug - MariTide - has shown significant weight loss within acceptable safety profiles in animal and early-stage human trials.

Starting a vegan or ketogenic diet can rapidly alter the immune system, a study reveals. Researchers found that switching to these diets triggers changes in the gut microbiome and immune cell populations within just four weeks.

Nanoform Finland Plc., the medicine performance-enhancing company, announced that one of its leading nanoformulation drug products had received promising relative bioavailability results from its clinical study of nanocrystalline-enabled enzalutamide (nanoenzalutamide) tablet formulation.

Medicine performance-enhancing specialists Nanoform announced it had completed a relative bioavailability study of its nanocrystalline enabled enzalutamide as an alternative to an amorphous solid dispersion formulation of Xtandi®, the leading prescribed androgen receptor inhibitor approved to treat prostate cancer.